Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 10/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986044 | 0.88 | FAAH (0.39) | CCR1 | |
| SCHEMBL4986102 | 0.87 | PKM (0.44) | POLBKMT2AAKR1C3 | |
| SCHEMBL4993377 | 0.85 | KMT2A (0.43) | CNR1ATMPOLBLMNAKMT2A | |
| SCHEMBL4986058 | 0.83 | USP2 (0.46) | CNR1ATMPOLBGAAKMT2A | |
| SCHEMBL4988448 | 0.83 | MEN1 (0.45) | MEN1GAAKMT2AAKR1C3AKR1C1 | |
| SCHEMBL4986140 | 0.83 | CNR1 (0.38) | CNR1GAAAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4988642 | 0.83 | MAPT (0.43) | MEN1LMNAKMT2ASMN1; SMN2AKR1C3 | |
| SCHEMBL4992564 | 0.82 | MEN1 (0.47) | MEN1LMNAGAAKMT2AAKR1C3 | |
| SCHEMBL4991400 | 0.82 | EPHX2 (0.41) | LMNASMN1; SMN2AKR1C3 | |
| SCHEMBL4989326 | 0.81 | ALDH1A1 (0.38) | ATMPOLBLMNAKMT2AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CNR1 49/4885MET 4499/4885ATM 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.